Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01968967 · ClinicalTrials.gov registry record · Phase 3
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,139
- Enrollment target
NCT01968967 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 2,139 participants.
The verdict
NCT01968967, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,139 participants
- Enrollment target
Study Summary
This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.
Interventions
- OTHER Placebo
- DRUG Bococizumab (PF-04950615; RN316)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,139 participants |
| Start Date | 2013-10-29 |
| Est. Completion | 2017-07-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01968967
The ClinicalTrials.gov registry entry for NCT01968967 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,139 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01968967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01968967 about?
NCT01968967 is a clinical study titled "Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events". This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.
What is the current status of trial NCT01968967?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,139 participants. The study started on 2013-10-29. Estimated completion is 2017-07-10.
What interventions are being tested in trial NCT01968967?
The interventions under investigation include: Placebo (OTHER), Bococizumab (PF-04950615; RN316) (DRUG).
Who is sponsoring clinical trial NCT01968967?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.